NASDAQ:IFRX InflaRx (IFRX) Stock Price, News & Analysis → Wall Street Legend Issues New NVDA Warning (From Chaikin Analytics) (Ad) Free IFRX Stock Alerts $1.30 -0.06 (-4.41%) (As of 10:39 AM ET) Add Compare Share Share Today's Range$1.27▼$1.3650-Day Range$1.26▼$1.7952-Week Range$1.14▼$5.20Volume39,850 shsAverage Volume235,842 shsMarket Capitalization$76.54 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get InflaRx alerts: Email Address InflaRx MarketRank™ Stock AnalysisAnalyst RatingStrong Buy3.50 Rating ScoreUpside/Downside907.5% Upside$13.50 Price TargetShort InterestHealthy0.66% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.00) to ($0.93) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.20 out of 5 starsMedical Sector513th out of 907 stocksPharmaceutical Preparations Industry233rd out of 422 stocks 3.8 Analyst's Opinion Consensus RatingInflaRx has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageInflaRx has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.66% of the outstanding shares of InflaRx have been sold short.Short Interest Ratio / Days to CoverInflaRx has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InflaRx has recently increased by 22.86%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInflaRx does not currently pay a dividend.Dividend GrowthInflaRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IFRX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for InflaRx this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for IFRX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added InflaRx to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, InflaRx insiders have not sold or bought any company stock.Percentage Held by Insiders16.30% of the stock of InflaRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.39% of the stock of InflaRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for InflaRx are expected to grow in the coming year, from ($1.00) to ($0.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InflaRx is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InflaRx is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInflaRx has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin AnalyticsWall Street Legend Issues New NVDA WarningLegendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.Click here for the stock details About InflaRx Stock (NASDAQ:IFRX)InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Read More IFRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IFRX Stock News HeadlinesApril 24, 2024 | globenewswire.comInflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters EventMarch 22, 2024 | markets.businessinsider.comBuy Rating Justified for InflaRx Despite Earnings Miss: Financial Stability and INF904’s Market PotentialApril 25, 2024 | Chaikin Analytics (Ad)Wall Street Legend Issues New NVDA WarningLegendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.March 21, 2024 | investorplace.comIFRX Stock Earnings: InflaRx Misses EPS, Misses Revenue for Q4 2023March 21, 2024 | globenewswire.comInflaRx Reports Full Year 2023 Results and Announces INF904 Development PlansMarch 20, 2024 | benzinga.com6IFRX : Earnings Preview: InflaRxMarch 19, 2024 | globenewswire.comInflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024March 6, 2024 | finance.yahoo.comIs InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?April 25, 2024 | Chaikin Analytics (Ad)Wall Street Legend Issues New NVDA WarningLegendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.February 22, 2024 | investing.comInflaRx N.V. (IFRX)February 22, 2024 | finance.yahoo.comInflaRx Appoints Jan Medina as Head of Investor RelationsFebruary 22, 2024 | globenewswire.comInflaRx Appoints Jan Medina as Head of Investor RelationsFebruary 17, 2024 | finance.yahoo.comIFRX Apr 2024 2.500 callJanuary 25, 2024 | markets.businessinsider.comBuy Recommendation for InflaRx Amidst Strategic Initiatives and Promising Clinical AdvancesJanuary 25, 2024 | finanznachrichten.deInflaRx N.V.: InflaRx Announces Initiation of its Commitment Program for GOHIBIC(vilobelimab) to Help Broaden Access for Eligible PatientsJanuary 25, 2024 | finance.yahoo.comInflaRx N.V.'s (NASDAQ:IFRX) top owners are individual investors with 55% stake, while 23% is held by institutionsJanuary 25, 2024 | finance.yahoo.comInflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible PatientsJanuary 6, 2024 | markets.businessinsider.comInflaRx’s Promising INF904 Phase 1 Results Prompt Buy RatingJanuary 4, 2024 | finanznachrichten.deInflaRx N.V.: InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904January 4, 2024 | markets.businessinsider.comInflaRx's MAD Part Phase 1 Trial For INF904 Reports Positive ResultsJanuary 4, 2024 | finance.yahoo.comInflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904December 1, 2023 | finance.yahoo.comHere's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom FishingNovember 28, 2023 | finance.yahoo.comAfter Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)November 20, 2023 | morningstar.comInflaRx NV IFRXNovember 7, 2023 | markets.businessinsider.comBuy Rating for InflaRx: Potential Breakthrough PG Treatment and Promising Revenue ForecastsNovember 6, 2023 | finance.yahoo.comInflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerNovember 6, 2023 | finance.yahoo.comInflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma GangrenosumSee More Headlines Receive IFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IFRX CUSIPN/A CIK1708688 Webwww.inflarx.de Phone493641508180Fax49-36-4150-8181Employees62Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$19.00 Low Stock Price Target$8.00 Potential Upside/Downside+907.5%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,180,000.00 Net MarginsN/A Pretax Margin-67,630.59% Return on Equity-40.10% Return on Assets-36.24% Debt Debt-to-Equity RatioN/A Current Ratio6.50 Quick Ratio5.82 Sales & Book Value Annual Sales$70,000.00 Price / Sales1,127.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.89 per share Price / Book0.71Miscellaneous Outstanding Shares58,880,000Free Float49,285,000Market Cap$78.90 million OptionableOptionable Beta1.27 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Niels C. Riedemann M.D. (Age 51)Ph.D., Co-Founder, CEO & Executive Director Prof. Renfeng Guo M.D. (Age 54)Co-Founder, Chief Scientific Officer & Executive Director Dr. Thomas Taapken Ph.D. (Age 59)Chief Financial Officer Ms. Derval O'Carroll (Age 58)Senior VP and Global Head of Regulatory Affairs & Compliance Dr. Camilla Chong M.D. (Age 58)Chief Medical Officer Mr. Jan Medina CFAHead of Investor Relations & VPMr. Christian SchmidVP and Head of Legal Affairs & General CounselMs. Nicole BertschSenior Director & Head of Human ResourcesDr. Maria Habel PH.D. (Age 42)VP, Head of Preclinical R&D and QC Dr. Bruce P. Burnett Ph.D.VP & Head of Medical AffairsMore ExecutivesKey CompetitorsOncolytics BiotechNASDAQ:ONCYAileron TherapeuticsNASDAQ:ALRNMarinus PharmaceuticalsNASDAQ:MRNSAffimedNASDAQ:AFMDLeap TherapeuticsNASDAQ:LPTXView All CompetitorsInstitutional OwnershipAffinity Asset Advisors LLCSold 125,000 shares on 2/13/2024Ownership: 0.448%View All Institutional Transactions IFRX Stock Analysis - Frequently Asked Questions Should I buy or sell InflaRx stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InflaRx in the last year. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "strong buy" IFRX shares. View IFRX analyst ratings or view top-rated stocks. What is InflaRx's stock price target for 2024? 2 brokers have issued 12 month price objectives for InflaRx's stock. Their IFRX share price targets range from $8.00 to $19.00. On average, they expect the company's share price to reach $13.50 in the next twelve months. This suggests a possible upside of 907.5% from the stock's current price. View analysts price targets for IFRX or view top-rated stocks among Wall Street analysts. How have IFRX shares performed in 2024? InflaRx's stock was trading at $1.63 on January 1st, 2024. Since then, IFRX shares have decreased by 17.8% and is now trading at $1.34. View the best growth stocks for 2024 here. Are investors shorting InflaRx? InflaRx saw a increase in short interest in March. As of March 31st, there was short interest totaling 389,100 shares, an increase of 22.9% from the March 15th total of 316,700 shares. Based on an average trading volume of 234,200 shares, the days-to-cover ratio is currently 1.7 days. View InflaRx's Short Interest. When is InflaRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our IFRX earnings forecast. How were InflaRx's earnings last quarter? InflaRx (NASDAQ:IFRX) issued its quarterly earnings data on Thursday, March, 21st. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.10. What ETF holds InflaRx's stock? Amplify Treatments, Testing and Advancements ETF holds 13,925 shares of IFRX stock, representing 0.21% of its portfolio. What other stocks do shareholders of InflaRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), Kadmon (KDMN) and Moderna (MRNA). When did InflaRx IPO? InflaRx (IFRX) raised $100 million in an IPO on Wednesday, November 8th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. How do I buy shares of InflaRx? Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IFRX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWall Street Legend Issues New NVDA WarningChaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
